Processa Pharmaceuticals Enters Material Definitive Agreement

Ticker: PCSA · Form: 8-K · Filed: May 21, 2024 · CIK: 1533743

Processa Pharmaceuticals, Inc. 8-K Filing Summary
FieldDetail
CompanyProcessa Pharmaceuticals, Inc. (PCSA)
Form Type8-K
Filed DateMay 21, 2024
Risk Levelmedium
Pages3
Reading Time4 min
Key Dollar Amounts$0.0001, $2.4 million
Sentimentneutral

Sentiment: neutral

Topics: material-definitive-agreement, pharmaceuticals

TL;DR

Processa Pharma just signed a big deal, filing an 8-K today.

AI Summary

On May 21, 2024, Processa Pharmaceuticals, Inc. entered into a material definitive agreement. The company, previously known as Heatwurx, Inc., is incorporated in Delaware and operates in the pharmaceutical preparations sector.

Why It Matters

This filing indicates a significant new agreement for Processa Pharmaceuticals, which could impact its future operations and financial performance.

Risk Assessment

Risk Level: medium — Entering into material definitive agreements can carry inherent risks related to the terms, execution, and potential impact on the company's financial health.

Key Players & Entities

  • Processa Pharmaceuticals, Inc. (company) — Registrant
  • Heatwurx, Inc. (company) — Former company name
  • May 21, 2024 (date) — Date of earliest event reported

FAQ

What is the nature of the material definitive agreement Processa Pharmaceuticals entered into?

The filing does not specify the details of the material definitive agreement, only that one was entered into on May 21, 2024.

When was Processa Pharmaceuticals, Inc. incorporated?

Processa Pharmaceuticals, Inc. was incorporated in Delaware.

What was the previous name of Processa Pharmaceuticals, Inc.?

The previous name of Processa Pharmaceuticals, Inc. was Heatwurx, Inc., with a name change date of October 28, 2011.

What is the principal executive office address for Processa Pharmaceuticals, Inc.?

The principal executive office is located at 7380 Coca Cola Drive, Suite 106, Hanover, Maryland 21076.

What is the Standard Industrial Classification (SIC) code for Processa Pharmaceuticals, Inc.?

The SIC code for Processa Pharmaceuticals, Inc. is 2834, which corresponds to Pharmaceutical Preparations.

Filing Stats: 915 words · 4 min read · ~3 pages · Grade level 11.5 · Accepted 2024-05-21 16:13:45

Key Financial Figures

  • $0.0001 — nge on Which Registered Common Stock, $0.0001 par value per share PCSA The Nasdaq
  • $2.4 million — ng an aggregate offering price of up to $2.4 million from time to time through or to our Sal

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PROCESSA PHARMACEUTICALS, INC. /s/ George Ng Date: May 21, 2024 George Ng Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.